Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 589

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 589
---
 of New Semnur Common Stock: (a) 8,235,378 Public Warrants outstanding, (b) 14,622 Public Warrants underlying the Public Units, (c) 510,000 Denali Private Placement Warrants underlying the Denali Private Placement Units, and (d) 50,000,000 options to acquire shares of New Semnur Common Stock that may be issued to Semnur option holders in connection with the Business Combination (assuming approval of the Option Exchange Proposal). Similarly, up to 6,000,000 shares of New Semnur Series A Preferred Stock that may be issued to Scilex in connection with the Business Combination are also excluded because such shares are not legally convertible into shares of New Semnur Common Stock.

| (2) | The shares of New Semnur Series A Preferred Stock are considered participating securities. Thus, the two-class method is required in determining basic EPS. However, given the holders of New Semnur Series A Preferred Stock are not contractually obligated to share in the losses of New Semnur, the two-class method and subsequent allocation of loss will not be used when New Semnur is in a net loss position. Thus, and as no dividends or distributions have been declared, the shares of New Semnur Series A Preferred Stock have no impact to the calculations of basic EPS. Further, given the shares of New Semnur Series A Preferred Stock are not legally convertible into shares of New Semnur Common Stock, there will be no incremental changes to the dilutive EPS calculation. |

358

DIRECTORS AND EXECUTIVE OFFICERS OF DENALI References in this section to “Denali,” “we,” “our” or “us” refer to Denali Capital Acquisition Corp. Current Directors and Executive Officers Denali’s current directors and officers are as follows:

| Name                |     | Age* |    |     | Position                             |
| Lei Huang           |     |      | 53 |     | Chief Executive Officer and Director |
| You (“Patrick”) Sun |     |      | 37 |     | Chief Financial Officer              |
| Huifeng Chang       |     |      | 59 |     | Director                             |
| Jim Mao             |     |      | 57 |     | Director                             |
| Kevin Vassily       |     |      | 58 |     | Director                             |

| * | Age as of the date of this proxy statement/prospectus. |

Lei Huang